Key Insights

Highlights

Treatment Research

3 treatments under study, led by Exv802

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 2/3 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT06803823Phase 2RecruitingPrimary

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

NCT07284472Phase 2/3RecruitingPrimary

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Showing all 2 trials

Research Network

Common Treatments

  • Exv8021
  • Ono20201
  • Exv8011

Active Sponsors

  • Ono Pharmaceutical Co., Ltd.1
  • Exciva GmbH1

Top Investigators

Related Conditions

  • Agitation In Alzheimers Disease Dementia1

Activity Timeline